文献速递妇科

妇科恶性肿瘤患者化疗毒性评估中的患者报告结局:一项先导研究

Patient reported outcomes in evaluation of chemotherapy toxicity in women with gynecologic malignancies: A pilot study.
PubMed 文献 · Gynecol Oncol · 2018-07-20

该先导研究于2017年4月至8月前瞻性纳入44例接受化疗的妇科恶性肿瘤患者,在两次门诊访视时使用24项症状患者报告结局问卷,评估患者和医生满意度。结果显示95%患者和97%医生认为问卷涵盖重要症状,69%患者和97%医生认为问卷对临床照护有积极影响,85%患者希望全程使用类似问卷。

要点

  • 95%患者和97%医生认为患者报告结局问卷涵盖了重要症状。
  • 69%患者和97%医生认为问卷对临床照护产生了积极影响。
  • 85%患者希望在整个治疗过程中使用类似问卷。

核心结论

  • 将聚焦的患者报告症状问卷纳入妇科肿瘤化疗患者的常规门诊照护,在问卷内容、可行性和照护改善感知方面获得患者和医生的高度满意度。

研究设计与样本

  • 前瞻性先导研究,经IRB批准后于2017年4月至2017年8月前瞻性识别接受化疗的妇科恶性肿瘤患者,共纳入44例。

主要发现

  • 患者种族多样:52%白人、18%非裔美国人、9%亚裔、20%其他;27%为西班牙裔。
  • 多数患者为卵巢癌(54%),其次为子宫癌(29%)和宫颈癌(15%)。
  • 95%患者和97%医生的满意度调查应答表示问卷涵盖了重要症状。
  • 几乎所有患者和医生的应答均表示问卷易于使用。
  • 69%患者和97%医生的应答表示问卷对临床照护有积极影响;85%患者希望在整个治疗过程中使用类似问卷。

关键数值与推荐

  • 使用改编自经验证的患者报告结局版常见不良事件术语标准的24项症状问卷,在两次门诊访视开始时发放。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patient reported outcomes (PRO) relating to treatment toxicities have been demonstrated to reliably evaluate adverse events in clinical trials. We assessed the user satisfaction of implementing a focused PRO questionnaire for patients with gynecologic cancers undergoing chemotherapy. METHODS: Patients with gynecologic cancers undergoing chemotherapy were prospectively identified after IRB approval from April 2017 to August 2017. We administered a 24-symptom questionnaire, adapted from the validated PRO version of the Common Terminology Criteria for Adverse Event, to enrolled participants at the beginning of two outpatient visits. Patient and provider satisfaction with use of PRO was assessed afterwards. Descriptive statistics were performed. RESULTS: A total of 44 patients were enrolled. Patients were racially diverse: 52% Caucasian, 18% African-American, 9% Asian, and 20% other; 27% were of Hispanic origin. The majority of patients had ovarian cancer (54%), followed by uterine (29%) and cervical cancer (15%). Ninety-five percent of patient and 97% of provider satisfaction survey responses indicated the PRO questionnaire addressed important symptoms. Nearly all patient and provider responses indicated the PRO questionnaire was easy to use. Sixty-nine percent of patient and 97% of provider responses indicated the questionnaire positively impacted clinical care; 85% of patients wished to use a similar questionnaire throughout treatment. CONCLUSIONS: We have shown that incorporating a focused patient-reported symptom questionnaire into routine outpatient care of gynecological oncology patients undergoing chemotherapy was met with a high degree of patient and provider satisfaction regarding questionnaire content, feasibility, and perception of care improvement.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Webster EM, Burke WM, Ware HM, et al. Patient reported outcomes in evaluation of chemotherapy toxicity in women with gynecologic malignancies: A pilot study. Gynecol Oncol. 2018. PMID: 30037492. doi:10.1016/j.ygyno.2018.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。